로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Envelope protein

Envelope protein

요약

Name:Recombinant envelope protein
Target Synonym:env,Submitted name: Recombinant envelope protein,Viral Envelope Proteins
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
결합물별:
제품번호 제품 설명 구조 순도 특징
ENN-C5128 SARS-CoV-2 SARS-CoV-2 (COVID-19) Envelope protein, GST,His Tag
ENN-C5128-structure
ENN-C5128-sds

Synonym Name

Envelope protein,Env polyprotein,Envelope glycoprotein,env

Background

The SARS-CoV-2 is composed of a double-layered lipid envelope, including Spike glycoprotein (S), Envelope protein (E), Membrane glycoprotein (M), and Nucleocapsid protein (Nucleocapsid protein, N). Among them, The amino acid sequence of the SARS-CoV-2 envelope protein is 95% identical of the SARS envelope protein.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tecovirimat SIGA-246; ST-246 Approved Siga Technologies Inc Tpoxx United States Smallpox Siga Technologies Inc 2018-07-13 Smallpox; Cowpox; Vaccinia; Poxviridae Infections; Monkeypox Details
Tecovirimat SIGA-246; ST-246 Approved Siga Technologies Inc Tpoxx United States Smallpox Siga Technologies Inc 2018-07-13 Smallpox; Cowpox; Vaccinia; Poxviridae Infections; Monkeypox Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Targeting HIV-1 Env gp140 antibodies Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
Temelimab GNN-001; GENHP-01; GNbAC-1 Phase 2 Clinical Geneuro Sa Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Multiple Sclerosis; Post-Acute COVID-19 Syndrome Details
PGDM-1400 PGDM-1400; PGDM1400LS Phase 2 Clinical International Aids Vaccine Initiative HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity Details
VIS-513 VIS-513; Ab-513 Phase 1 Clinical Otsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra Inc Dengue Details
Targeting HIV-1 Env gp140 antibodies Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
Temelimab GNN-001; GENHP-01; GNbAC-1 Phase 2 Clinical Geneuro Sa Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Multiple Sclerosis; Post-Acute COVID-19 Syndrome Details
PGDM-1400 PGDM-1400; PGDM1400LS Phase 2 Clinical International Aids Vaccine Initiative HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity Details
VIS-513 VIS-513; Ab-513 Phase 1 Clinical Otsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra Inc Dengue Details

This web search service is supported by Google Inc.

totop